切换至 "中华医学电子期刊资源库"
高级检索
中华乳腺病杂志(电子版)

中华乳腺病杂志(电子版) ›› 2024, Vol. 18 ›› Issue (04) : 193 -198. doi: 10.3877/cma.j.issn.1674-0807.2024.04.001

专家论坛

精准医学时代乳腺癌腋窝淋巴结的管理
林丽1, 杨英1, 张毅1,†()   
  1. 1. 400038　重庆，陆军军医大学第一附属医院乳腺甲状腺外科；400038　重庆，重庆市卫生健康委员会乳腺癌微创和精准诊疗重点实验室
  • 收稿日期:2024-04-28 出版日期:2024-08-01
  • 通信作者: 张毅

Management of axillary lymph nodes in breast cancer in the era of precision medicine

Li Lin1, Ying Yang1, Yi Zhang1,†()   

  1. 1. Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing 400030, China; Key Laboratory of Chongqing Health Commission for Minimally Invasive and Precise Diagnosis and Treatment of Breast Cancer, Chongqing 400030, China
  • Received:2024-04-28 Published:2024-08-01
  • Corresponding author: Yi Zhang
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

林丽, 杨英, 张毅. 精准医学时代乳腺癌腋窝淋巴结的管理[J]. 中华乳腺病杂志(电子版), 2024, 18(04): 193-198.

Li Lin, Ying Yang, Yi Zhang. Management of axillary lymph nodes in breast cancer in the era of precision medicine[J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(04): 193-198.

乳腺癌的全身系统化治疗策略正逐步发生改变，其中，内分泌治疗和靶向治疗等内科治疗方法不断被强化，而外科治疗领域步入了精准治疗时代，特别是在腋窝淋巴结管理方面。传统的腋窝淋巴结清扫逐渐被前哨淋巴结活组织检查(SLNB)所替代。SLNB通过精确检测腋窝淋巴结转移情况，减少了不必要的腋窝清扫，降低了术后并发症如淋巴水肿的风险，显著提高了患者术后的生活质量。本文总结了近年来腋窝淋巴结管理相关的高质量临床研究，证实了SLNB的安全性和有效性，并针对前哨淋巴结微转移和宏转移的患者，探讨了差异化的治疗策略。此外，本文分析了新辅助化疗后腋窝淋巴结管理的现状，并探讨了通过精准评估进一步豁免SLNB的潜力。腋窝淋巴结管理的精准化是乳腺癌外科治疗的重要进步，可以显著减少术后并发症，也为乳腺癌的个体化治疗提供了有力证据。

关键词: 乳腺肿瘤, 精准医学, 前哨淋巴结

The systemic treatment strategy for breast cancer is gradually changing, among which medical treatments such as endocrine therapy and targeted therapy are being enhanced, and breast surgery has entered the era of precision medicine, especially for the management of axillary lymph nodes. Traditional axillary lymph node dissection is gradually replaced by sentinel lymph node biopsy (SLNB). SLNB can significantly reduce unnecessary axillary dissection and the risk of postoperative complications such as lymphedema by accurately detecting axillary lymph node metastases, thereby improving the quality of life of patients after surgery. This article summarized the high-quality clinical studies on axillary lymph node management in recent years, confirmed the safety and efficacy of SLNB, and discussed differentiated treatment strategies for patients with sentinel lymph node micrometastases and macrometastases. In addition, this article analyzed the current status of axillary lymph node management after neoadjuvant chemotherapy and explored the potential for further exemption from SLNB through accurate assessment. The precision management of axillary lymph nodes is a remarkable advancement in breast cancer surgery, which can significantly reduce postoperative complications, and also provide strong evidences for individualized treatment of breast cancer.

Key words: Breast neoplasms, Precision medicine, Sentinel lymph node
[1]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3)：209-249.
[2]
郑荣寿，陈茹，韩冰峰，等. 2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志，2024, 46(3)：221-231.
[3]
Chang JM, Leung JW, Moy L, et al. Axillary nodal evaluation in breast cancer：state of the art [J]. Radiology, 2020, 295(3)：500-515.
[4]
Halsted WS. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins hospital from June, 1889, to January, 1894 [J]. Ann Surg, 1894, 20(5)：497-555.
[5]
段学宁. 乳腺癌手术治疗百年历史回顾与启示[J].中国实用外科杂志，2018, 38(11)：1227-1231.
[6]
邬思雨，李俊杰，邵志敏. 乳腺癌前哨淋巴结活检术的发展历史及研究进展[J].中国癌症杂志，2023, 33(6)：551-559.
[7]
Krag DN, Weaver DL, Alex JC, et al. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe [J]. Surg Oncol, 1993, 2(6)：335-340
[8]
Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer [J]. JAMA, 1996，276(22)：1818-1822.
[9]
Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer [J]. N Engl J Med, 2003, 349(6)：546-453
[10]
Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast can cer：overall survival findings from the NSABP B-32 randomised phase 3 trial [J]. Lancet Oncol, 2010，11(10)：927-933.
[11]
Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard a xillary treatment in operable breast cancer：the ALMANAC Trial [J]. J Natl Cancer Inst, 2006, 98(9)：599-609.
[12]
Hunt KK, Ballman KV, Mccall LM, et al. Factors associated with local-regional recurrence after a negative sentinel node dissection：results of the ACOSOG Z0010 trial [J]. Ann Surg, 2012, 256(3)：428-436.
[13]
Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer [J]. J Clin Oncol, 2005, 23(30)：7703-7720.
[14]
Gipponi M, Fregatti P, Garlaschi A, et al. Axillary ultrasound and fine-needle aspiration cytology in the preoper ative staging of axillary node metastasis in breast cancer patients [J]. Breast, 2016, 30：146-150.
[15]
梁颖．早期乳腺癌患者术前腋窝超声检查评价腋窝淋巴结状态的临床研究[D].济南：山东大学，2021.
[16]
周鑫仪，冉海涛，张花. 影像学检查在乳腺癌前哨淋巴结中的应用进展[J].中国医学影像学杂志，2023, 31(5)：545-549.
[17]
朱芸，张书海，王小雷，等．基于MRI、钼靶和病理的列线图预测肿块型乳腺浸润性导管癌前哨淋巴结转移的价值[J].磁共振成像，2022, 13(5)：45-51.
[18]
Zhu T, Huang YH, Li W, et al. Multifactor artificial intelligence model assists axillary lymph node surgery in breast cancer after neoadjuvant chemotherapy：multicenter r etrospective cohort study [J]. Int J Surg, 2023, 109(11)：3383-3394.
[19]
Ashiba H, Nakayama R. Computerized evaluation scheme to detect metastasis in sentinel lymph nodes using contrast-enhanced computed tomography before breast cancer surgery [J]. Radiol Phys Technol, 2019，12(1)：55-60.
[20]
Sarikaya I, Sarikaya A. Assessing 18F-FDG uptake in the sentinel lymph node in breast cancer [J]. J Nucl Med Technol, 2019, 47(2)：149-153.
[21]
Reed J, Rosman M, Verbanac KM, et al. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer：10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center sentinel node multicenter study [J]. J Am Coll Surg, 2009, 208(3)：333-340.
[22]
Houvenaeghel G, Boher JM, Reyal F, et al. Impact of completion axillary lymph node dissection in patients with breast cancer and isolated tumour cells or micrometastases in sentinel nodes [J]. Eur J Cancer, 2016, 67：106-118.
[23]
Montagna G. Are nodal ITCs after neoadjuvant chemotherapy an indication for axillary dissection? The OPBC05/EUBREAST-14R/ICARO study [EB/OL].[2023-12-07].

URL    
[24]
Solá M, Alberro JA, Fraile M, et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis：final result s from the multicenter clinical trial AATRM 048/13/2000 [J]. Ann Surg Oncol, 2013, 20(1)：120-127.
[25]
Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01)：10-year follow-up of a randomised, controlled phase 3 trial [J]. Lancet Oncol, 2018, 19(10)：1385-1393.
[26]
Bevers TB, Helvie M, Bonaccio E, et al. Breast cancer screening and diagnosis，version 3.2018, NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2018, 16(11)：1362-1389.
[27]
Giuliano AE, Ballman KV, Mccall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis：the ACOSOG Z0011 (alliance) randomized clinical trial [J]. JAMA, 2017, 318(10)：918-926.
[28]
Bartels AL, Donker M, Poncrt C, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer：10-year results of the randomized controlled EORTC 10 981-22 023 AMAROS trial [J]. J Clin Oncol, 2023, 41(12)：2159-2165.
[29]
Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update [J]. J Clin Oncol, 2014, 32(13)：1365-1383.
[30]
De Boniface J, Filtenborg TT, Rydén L, et al. Omitting axillary dissection in breast cancer with sentinel-node metas tases [J]. N Engl J Med, 2024, 390(13)：1163-1175.
[31]
Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma：a metaanalysis [J]. Cancer, 2006, 106(1)：4-16.
[32]
Bonneau C, Hequet D, Estevez JP, et al. Impact of axillary dissection in women with invasive breast cancer who do not fit the Z0011 ACOSOG trial because of three or more metastatic sentinel lymph nodes [J]. Eur J Surg Oncol, 2015, 41(8)：998-1004.
[33]
Yoon KH, Park S, Kim JY, et al. Is the frozen section examination for sentinel lymph node necessary in early breast cancer patients? [J]. Ann Surg Treat Res, 2019, 97(2)：49-57.
[34]
Nair NS, Das A, Shet T, et al. Accuracy of intraoperative frozen section analysis of lymph nodes in women undergoing axillary sampling for treatment of breast cancer：single institution audit [J]. Clin Breast Cancer, 2023, 23(7)：e420-e423.
[35]
叶京明，郭宝良，张建国，等．中国早期乳腺癌前哨淋巴结活检手术临床实践指南(2022版)[J].中国实用外科杂志 2022, 42(2)：137-145.
[36]
Wong J, Yong WS, Thike AA, et al. False negative rate for intraoperative sentinel lymph node frozen section in patients with breast cancer：a retrospective analysis of patients in a single Asian institution [J]. J Clin Pathol, 2015, 68(7)：536-540.
[37]
Laury RJ, Gloyeske N, Mettman D, et al. Intraoperative sentinel lymph node evaluation in patients with node-positive breast cancer status post neoadjuvant systemic therapy - an institutional experience [J]. Ann Diagn Pathol, 2022, 60：152012
[38]
陈世梁，符志龙，吴文川．提高乳腺癌前哨淋巴结冷冻切片制作质量的体会[J].临床与实验病理学杂志，2019, 35(3)：361-362.
[39]
Zhang YJ, Mauel E, Talpe S. Update on sentinel lymph node methods and pathology in breast cancer [J]. Diagnostics (Basel), 2024，14(3)：252.
[40]
Lyman GH, Somerfield MR, Bosserman LD, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer ：American Society of Clinical Oncology clinical practice guideline update [J]. J Clin Oncol, 2017, 35(5)：561-564.
[41]
Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA)：a prospective, multicentre cohort study [J]. Lancet Oncol, 2013, 14(7)：609-618.
[42]
Boughey JC, Suman VJ, Mittendore EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer：the ACOSOG Z1071 (Alliance) clinical trial [J]. JAMA, 2013, 310(14)：1455-1461.
[43]
Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer：the SNFNAC study [J]. J Clin Oncol, 2015, 33(3)：258-264.
[44]
Simons JM, Van Nijnatten TJA, Van Der Pol CC, et al. Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer：a systematic review and meta-analysis [J]. Ann Surg, 2019, 269(3)：432-442.
[45]
Barrio AV, Montagna G, Mamtani A, et al. Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy-a rare event [J]. JAMA Oncol, 2021, 7(12)：1851-1855.
[46]
Martelli G, Barretta F, Miceli R, et al. Sentinel node biopsy alone or with axillary dissection in breast cancer patients after primary chemotherapy：long-term results of a prospective interventional study [J]. Ann Surg, 2022, 276(5)：e544-e552.
[47]
Morawitz J, Sigl B, Rubbert C, et al. Clinical decision support for axillary lymph node staging in newly diagnosed breast cancer patients based on 18F-FDG PET/MRI and machine learning [J]. J Nucl Med, 2023，64(2)：304-311.
[48]
邱鹏飞，王永胜. 前哨淋巴结时代乳腺癌的精准区域处理：演进与展望[J].中国癌症杂志，2022, 32(8)：680-687.
[49]
Gentilini OD, Botteri E, Sangalli C, et al. Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes：the SOUND randomized clinical trial [J]. JAMA Oncol, 2023, 9(11)：1557-1564.
[50]
Van Roozendaal LM, Vane MLG, Van Dalen T, et al. Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up：a Dutch randomized controlled multicentre trial (BOOG 2013-08) [J]. BMC Cancer, 2017, 17(1)：459.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J]. 中华医学超声杂志（电子版）, 2024, 21(06): 563-570.
[2] 刘炎东, 李恒宇. 新辅助化疗后乳腺癌局部区域的分期评估和治疗的降阶梯策略[J]. 中华乳腺病杂志(电子版), 2024, 18(03): 146-151.
[3] 伍梦妮, 徐志华, 陈彦. DTNBP1基因在三阴性乳腺癌中的作用及其预后价值[J]. 中华乳腺病杂志(电子版), 2024, 18(03): 158-168.
[4] 管枫, 罗斌, 柯晓康, 袁静萍. 少见部位转移性乳腺浸润性小叶癌临床病理特征分析[J]. 中华乳腺病杂志(电子版), 2024, 18(03): 169-174.
[5] 刘世佳, 陶新楠, 史晋宇, 吕文豪, 张亚芬. 乳酸脱氢酶A在乳腺癌中的作用[J]. 中华乳腺病杂志(电子版), 2024, 18(03): 175-179.
[6] 黄海, 周学鲁. 乳腺癌孤立性腹股沟淋巴结转移的诊治现状[J]. 中华乳腺病杂志(电子版), 2024, 18(03): 180-183.
[7] 张梅, 李朝阳, 侯令密. 乳腺癌腋窝淋巴结孤立肿瘤细胞转移的临床意义[J]. 中华乳腺病杂志(电子版), 2024, 18(03): 184-188.
[8] 曾德荣, 马琳, 李星瀚, 胡伟涛, 刘琦, 邓永强. 多聚ADP核糖聚合酶1在口腔鳞状细胞癌精准诊疗中的作用机制及转化价值[J]. 中华口腔医学研究杂志(电子版), 2024, 18(04): 269-275.
[9] 伍先权, 张立果, 周璇, 梁建深. 乳腺包裹性乳头状癌的临床病理与手术策略联系[J]. 中华普通外科学文献(电子版), 2024, 18(04): 294-297.
[10] 李雪, 韩萌萌, 冯雪园, 马宁. 人表皮生长因子受体2低表达乳腺癌的研究进展及挑战[J]. 中华普通外科学文献(电子版), 2024, 18(04): 308-312.
[11] 宋佳, 汪波, 孙凯律, 商江峰, 吴旦平, 肇毅. 吲哚菁绿荧光显影联合亚甲蓝染色在乳腺癌前哨淋巴结活检中的应用[J]. 中华普外科手术学杂志(电子版), 2024, 18(05): 498-501.
[12] 刘虹, 王品, 王彬, 任杰超, 张文杰, 吴剑, 刘莹. 经腋窝腔镜辅助保留乳头乳晕皮下腺体切除术+Ⅰ期胸肌前假体乳房重建术[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 419-422.
[13] 康乐平, 张琳, 万舟, 苟勇. 腔镜皮下腺体切除及腋窝淋巴结清扫加假体植入术治疗乳腺癌疗效及并发症分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 427-429.
[14] 张茴, 李一, 代美玲. 植入物在乳房重建中的应用进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(03): 349-352.
[15] 黄宏山, 陈成彩. 经淋巴管超声造影在乳腺癌前哨淋巴结诊断中的研究进展[J]. 中华临床医师杂志(电子版), 2024, 18(04): 411-414.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号